The debate on the subject of the healing effect of deuterium-depleted water in cancer therapy may come to an end, as two reputed scientists, Dr. Stephanie Seneff (MIT) and Anthony M. Kyriakopoulos (NASCO Ad Biotech), published their study on the role of DDW in cancer therapy.
The study, presented as a narrative review and initially published in the European Journal of Cancer Prevention, underlines the need to include DDW in the cancer therapy, while presenting scientific data on the subject.
“These complex processes suggest that cancer cells are able to sense deuterium levels in the medium and commit apoptosis when deuterium levels are low or proliferate when they are high. Tumorigenesis involves a metabolic switch that supports increased cellular deuterium levels, decreasing the deuterium burden overall in the organism. Strong clinical evidence supports deuterium-depleted water (DDW) as an anticancer treatment. More investigations on cancer autophagic behavior are needed to guide DDW clinical use.”
Also:
“A causal factor in oncogenesis is excess deuterium in mitochondria. Cells whose mitochondria are sufficiently damaged by deuterium may transform into tumor cells, and this transformation is associated with a readjustment of metabolism to reduce the need for mitochondria-derived energy.
Simultaneously, they engage in a program that results in further enrichment of cytoplasmic deuterium through the export of deupleted protons and the overproduction of lactate, a carrier of a deupleted proton derived from NADH, exported to the medium. C
ancer cells support deuterium sequestration and release deupleted nutrients, primarily lactate, to support neighboring immune cells and distant organs. The lactate and acidic pH produced by cancer cells lead to cancer progression and immunosuppression of resident immune cells.”
READ THIS SCIENTIFIC STUDY ON DDW BY CLICKING ON THE LINK BELOW:
Explaining Deuterium-depleted Water As A Cancer Therapy
